Cannabis Dependence
Disease Details
Family Health Simplified
- Description
- Cannabis dependence is a condition characterized by a compulsive need to use cannabis, despite adverse effects on daily life, and experiencing withdrawal symptoms when not using it.
- Type
- Cannabis dependence is primarily considered a substance use disorder. The genetic transmission of cannabis dependence is complex and not attributed to a single gene. It involves multiple genetic factors, with heritability estimates suggesting that genetic influences account for approximately 40-60% of the risk. This indicates a polygenic inheritance pattern, where many genes contribute small effects to the overall risk of developing cannabis dependence.
- Signs And Symptoms
- Cannabis use is sometimes comorbid for other mental health problems, such as mood and anxiety disorders, and discontinuing cannabis use is difficult for some users. Psychiatric comorbidities are often present in dependent cannabis users including a range of personality disorders.Based on annual survey data, some high school seniors who report smoking daily (nearly 7%, according to one study) may function at a lower rate in school than students that do not. The sedating and anxiolytic properties of tetrahydrocannabinol (THC) in some users might make the use of cannabis an attempt to self-medicate personality or psychiatric disorders.
- Prognosis
- Prognosis for cannabis dependence can vary widely depending on several factors including the individual's level of dependence, motivation to quit, presence of co-occurring mental health disorders, and access to support and treatment. Many individuals who seek treatment can achieve significant improvement and potentially long-term abstinence, although relapse is common. Behavioral therapies, such as cognitive-behavioral therapy (CBT), and support groups can enhance the likelihood of successful recovery. Treatment outcomes improve with sustained effort and support.
- Onset
- The onset of cannabis dependence can vary significantly between individuals, often influenced by genetic, environmental, and psychological factors. It typically develops after prolonged and regular use of cannabis. The pattern of use, age at initial use, and frequency and dosage of consumption can all play roles in the timeline of dependence formation. There is no specific age or duration universally defining the onset of cannabis dependence, as it depends on individual circumstances and risk factors.
- Prevalence
- The National Epidemiologic Survey on Alcohol and Related Conditions (NESARC) reports that the prevalence of cannabis dependence in the United States is approximately 1.5%. This condition involves a pattern of cannabis use leading to significant impairment or distress, accompanied by behaviors such as tolerance, withdrawal, and a persistent desire to use the substance despite adverse consequences.
- Epidemiology
- According to the 2022 National Survey on Drug Use and Health, cannabis is one of the most widely used drugs in the world. Research by the Pew Research Center from 2012 claims 42% of the US population have claimed to use cannabis at some point. According to the 2019 National Survey on Drug Use and Health, 46% of U.S. adults say they have ever used marijuana. An estimated 9% of those who use cannabis develop dependence.In the U.S., cannabis is the most commonly identified illicit substance used by people admitted to treatment facilities. Most of these people were referred there by the criminal justice system. Of admittees 16% either went on their own, or were referred by family or friends.Of Australians aged 14 years and over 34.8% have used cannabis one or more times in their life.In the European Union (data as available in 2018, information for individual countries was collected between 2012 and 2017), 26.3% of adults aged 15–64 used cannabis at least once in their lives, and 7.2% used cannabis in the last year. The highest prevalence of cannabis use among 15 to 64 years old in the EU was reported in France, with 41.4% having used cannabis at least once in their life, and 2.17% used cannabis daily or almost daily. Among young adults (15–34 years old), 14.1% used cannabis in the last year.Among adolescents (15–16 years old) in a European school based study (ESPAD), 16% of students have used cannabis at least once in their life, and 7% (boys: 8%, girls: 5%) of students had used cannabis in the last 30 days.Globally, 22.1 million people (0.3% of the worlds population) were estimated to have cannabis dependence.
- Intractability
- Cannabis dependence can be challenging to treat, but it is not generally considered intractable. With appropriate interventions, including behavioral therapies, support groups, and sometimes pharmacotherapy, many individuals can achieve and maintain abstinence. Long-term success often requires a comprehensive approach and ongoing support.
- Disease Severity
- Cannabis dependence is typically considered a moderate severity substance use disorder. It is characterized by a problematic pattern of cannabis use leading to significant impairment or distress, which can include symptoms like tolerance, withdrawal, unsuccessful attempts to cut down, and continued use despite negative consequences. The severity varies depending on the number and intensity of symptoms experienced by the individual.
- Healthcare Professionals
- Disease Ontology ID - DOID:1849
- Pathophysiology
- Cannabis dependence is characterized by the compulsive use of cannabis, leading to significant impairment or distress. The pathophysiology involves changes in the brain's reward system, particularly the endocannabinoid system, which includes cannabinoid receptors (CB1 and CB2). Chronic use of cannabis can lead to alterations in neurotransmitter release and receptor density, resulting in tolerance, withdrawal symptoms, and cravings. These changes are primarily mediated through the interaction of delta-9-tetrahydrocannabinol (THC), the main psychoactive component of cannabis, with the CB1 receptors located in the brain.
- Carrier Status
- Cannabis dependence does not involve a carrier status. Carrier status typically pertains to genetic conditions transmitted through genes, whereas cannabis dependence is a behavioral condition resulting from habitual use of cannabis. It is characterized by a pattern of continued cannabis use despite significant problems related to its use.
- Mechanism
-
Cannabis dependence is characterized by a compulsive need to use cannabis despite detrimental effects on one's life. The molecular mechanisms underlying cannabis dependence involve the endocannabinoid system, which includes cannabinoid receptors (CB1 and CB2), endogenous ligands (endocannabinoids), and enzymes responsible for the synthesis and degradation of these ligands.
1. **CB1 Receptors**: Predominantly located in the central nervous system, especially in brain areas involved in reward, mood, and cognitive function (e.g., hippocampus, amygdala, basal ganglia, and cerebral cortex).
2. **CB2 Receptors**: Primarily found in peripheral tissues and immune cells but are also present in the brain, though to a lesser extent.
**Mechanism**:
- **Acute use**: THC (delta-9-tetrahydrocannabinol), the active component of cannabis, binds to CB1 receptors, producing psychoactive effects such as euphoria and altered perception. This binding activates the dopaminergic pathways in the brain's reward system, notably the mesolimbic pathway, leading to increased dopamine release in areas such as the nucleus accumbens.
- **Chronic use**: Prolonged stimulation of CB1 receptors results in their downregulation and desensitization. This reduces receptor density and inhibits the endogenous endocannabinoid system's normal functioning, which contributes to tolerance (needing more cannabis to achieve the same effect) and dependence.
**Molecular Mechanisms**:
- **Endocannabinoids**: Anandamide (AEA) and 2-arachidonoylglycerol (2-AG) are the main endogenous ligands. They are synthesized on-demand from membrane lipids and act on pre-synaptic CB1 receptors to inhibit the release of various neurotransmitters (e.g., GABA, glutamate).
- **Signal Transduction**: THC binding to CB1 receptors leads to the activation of G-proteins, which then influence various intracellular effectors such as adenylate cyclase (decreasing cAMP levels), and ion channels (inhibiting calcium channels and activating potassium channels), ultimately reducing neurotransmitter release.
- **Neuroadaptation**: Chronic THC exposure alters the expression and sensitivity of CB1 and CB2 receptors and impacts the release and function of endocannabinoids. The changes in receptor expression and neurotransmitter release contribute to the withdrawal symptoms and craving when cannabis use is reduced or stopped.
These molecular and neurochemical changes underpin the development of dependence, as the brain's reward circuitry and neurotransmitter systems become progressively altered with sustained cannabis use. - Treatment
- Clinicians differentiate between casual users who have difficulty with drug screens, and daily heavy users, to a chronic user who uses multiple times a day. In the US, as of 2013, cannabis is the most commonly identified illicit substance used by people admitted to treatment facilities. Demand for treatment for cannabis use disorder increased internationally between 1995 and 2002. In the United States, the average adult who seeks treatment has consumed cannabis for over 10 years almost daily and has attempted to quit six or more times.Treatment options for cannabis dependence are far fewer than for opiate or alcohol dependence. Most treatment falls into the categories of psychological or psychotherapeutic, intervention, pharmacological intervention or treatment through peer support and environmental approaches. No medications have been found effective for cannabis dependence, but psychotherapeutic models hold promise. Screening and brief intervention sessions can be given in a variety of settings, particularly at doctor's offices, which is of importance as most cannabis users seeking help will do so from their general practitioner rather than a drug treatment service agency.The most commonly accessed forms of treatment in Australia are 12-step programmes, physicians, rehabilitation programmes, and detox services, with inpatient and outpatient services equally accessed. In the EU approximately 20% of all primary admissions and 29% of all new drug clients in 2005, had primary cannabis problems. And in all countries that reported data between 1999 and 2005 the number of people seeking treatment for cannabis use increased.
- Compassionate Use Treatment
-
Compassionate use treatment for cannabis dependence typically involves the use of medications or therapies that are not widely approved but may offer potential benefits. Some off-label or experimental treatments for cannabis dependence include:
1. **N-Acetylcysteine (NAC)**: An antioxidant supplement sometimes used to reduce cravings and withdrawal symptoms.
2. **Gabapentin**: Originally approved for seizures and neuropathic pain, it has been studied for reducing cannabis withdrawal symptoms.
3. **Topiramate**: An anticonvulsant that has shown some promise in helping with cannabis dependence by altering neurotransmitter systems involved in addiction.
4. **Cannabidiol (CBD)**: A non-psychoactive component of cannabis that has been explored for reducing cravings and anxiety associated with withdrawal.
5. **Contingency Management (Behavioral Therapy)**: Though not a drug, this behavioral approach offers non-monetary rewards for staying abstinent.
Experimental treatments should always be discussed with a healthcare provider to evaluate their safety and appropriateness for individual cases. - Lifestyle Recommendations
-
For cannabis dependence, the following lifestyle recommendations can help support recovery and overall well-being:
1. **Healthy Diet**: Consume a balanced diet rich in fruits, vegetables, whole grains, lean proteins, and healthy fats. Proper nutrition can aid in physical and mental health recovery.
2. **Adequate Sleep**: Aim for 7-9 hours of quality sleep per night. Good sleep hygiene, such as maintaining a regular sleep schedule and creating a restful sleeping environment, is crucial.
3. **Regular Exercise**: Engage in regular physical activity, such as walking, running, swimming, or yoga. Exercise can improve mood and reduce cravings by releasing endorphins.
4. **Support Networks**: Seek support from friends, family, or support groups. Joining a community of individuals with similar experiences, such as Narcotics Anonymous or counseling groups, can provide emotional support and reduce feelings of isolation.
5. **Stress Management**: Practice stress-relief techniques such as mindfulness meditation, deep-breathing exercises, or hobbies that you enjoy. Managing stress can decrease the desire to use cannabis as a coping mechanism.
6. **Professional Help**: Consider engaging with a healthcare provider, counselor, or therapist who specializes in addiction treatment. Cognitive-behavioral therapy (CBT) can be particularly effective in addressing cannabis dependence.
7. **Avoid Triggers**: Identify and avoid situations, places, or people that trigger the urge to use cannabis. Creating a new daily routine can help reduce exposure to these triggers.
8. **Set Goals**: Establish clear, achievable goals for reducing cannabis use and improving other areas of your life. Celebrate progress and milestones along the way to stay motivated.
Implementing these lifestyle changes can significantly aid in overcoming cannabis dependence and promote long-term health. - Medication
- As of 2020, there is no single medication that has been proven effective for treating cannabis use disorder; research is focused on three treatment approaches: agonist substitution, antagonist, and modulation of other neurotransmitter systems. More broadly, the goal of medication therapy for cannabis use disorder centers around targeting the stages of the addiction: acute intoxication/binge, withdrawal/negative affect, and preoccupation/anticipation.For the treatment of the withdrawal/negative affect symptom domain of cannabis use disorder, medications may work by alleviating restlessness, irritable or depressed mood, anxiety, and insomnia. Bupropion, which is a norepinephrine–dopamine reuptake inhibitor, has been studied for the treatment of withdrawal with largely poor results. Atomoxetine has also shown poor results, and is as a norepinephrine reuptake inhibitor, though it does increase the release of dopamine through downstream effects in the prefrontal cortex (an area of the brain responsible for planning complex tasks and behavior). Venlafaxine, a serotonin–norepinephrine reuptake inhibitor, has also been studied for cannabis use disorder, with the thought that the serotonergic component may be useful for the depressed mood or anxious dimensions of the withdrawal symptom domain. While venlafaxine has been shown to improve mood for people with cannabis use disorder, a clinical trial in this population actually found worse cannabis abstinence rates compared to placebo. It is worth noting that venlafaxine is sometimes poorly tolerated, and infrequent use or abrupt discontinuation of its use can lead to withdrawal symptoms from the medication itself, including irritability, dysphoria, and insomnia. It is possible that venlafaxine use actually exacerbated cannabis withdrawal symptoms, leading people to use more cannabis than placebo to alleviate their discomfort. Mirtazapine, which increases serotonin and norepinephrine, has also failed to improve abstinence rates in people with cannabis use disorder.People sometimes use cannabis to cope with their anxiety, and cannabis withdrawal can lead to symptoms of anxiety. Buspirone, a serotonin 1A receptor (5-HT1A) agonist, has shown limited efficacy for treating anxiety in people with cannabis use disorder, though there may be better efficacy in males than in females. Fluoxetine, a selective serotonin reuptake inhibitor, has failed to show efficacy in adolescents with both cannabis use disorder and depression. SSRIs are a class of antidepressant drugs that are also used for the treatment of anxiety disorders, such as generalized anxiety disorder. Vilazodone, which has both SSRI and 5-HT1A agonism properties, also failed to increase abstinence rates in people with cannabis use disorder.Studies of divalproex have found no significant benefit, though some studies have found mixed results. Baclofen, a GABAB receptor agonist and antispasmodic medication, has been found to reduce cravings but without a significant benefit towards preventing relapse or improving sleep. Zolpidem, a GABAA receptor agonist and "Z-hypnotic" medication, has shown some efficacy in treating insomnia due to cannabis withdrawal, though there is a potential for misuse. Entacapone was well tolerated and decreased cannabis cravings in a trial on a small number of patients. Topiramate, an antiepileptic drug, has shown mixed results in adolescents, reducing the volume of cannabis consumption without significantly increasing abstinence, with somewhat poor tolerability. Gabapentin, an indirect GABA modulator, has shown some preliminary benefit for reducing cravings and cannabis use.The agonist substitution approach is one that draws upon the analogy of the success of nicotine replacement therapy for nicotine addiction. Dronabinol, which is synthetic THC, has shown benefit in reducing cravings and other symptoms of withdrawal, though without preventing relapse or promoting abstinence. Combination therapy with dronabinol and the α2-adrenergic receptor agonist lofexidine have shown mixed results, with possible benefits towards reducing withdrawal symptoms. However, overall, the combination of dronabinol and lofexidine is likely not effective for the treatment of cannabis use disorder. Nabilone, a synthetic THC analogue, has shown benefits in reducing symptoms of withdrawal such as difficulty sleeping, and decreased overall cannabis use. Despite its psychoactive effects, the slower onset of action and longer duration of action of nabilone make it less likely to be abused than cannabis itself, which makes nabilone a promising harm reduction strategy for the treatment of cannabis use disorder. The combination of nabilone and zolpidem has been shown to decrease sleep-related and mood-related symptoms of cannabis withdrawal, in addition to decreasing cannabis use. Nabiximols, a combined THC and cannabidiol (CBD) product that is formulated as an oral (buccal) spray, has been shown to improve withdrawal symptoms without improving abstinence rates. Oral CBD has not shown efficacy in reducing the signs or symptoms of cannabis use, and likely has no benefit in cannabis use withdrawal symptoms. The CB1 receptor antagonist rimonabant has shown efficacy in reducing the effects of cannabis in users, but with a risk for serious psychiatric side effects.Naltrexone, a μ-opioid receptor antagonist, has shown mixed results for cannabis use disorder—both increasing the subjective effects of cannabis when given acutely, but potentially decreasing the overall use of cannabis with chronic administration. N-acetylcysteine (NAC) has shown some limited benefit in decreasing cannabis use in adolescents, though not with adults. Lithium, a mood stabilizer, has shown mixed results for treating symptoms of cannabis withdrawal, but is likely ineffective. Quetiapine, a second-generation antipsychotic, has been shown to treat cannabis withdrawal related insomnia and decreased appetite at the expense of exacerbating cravings. Oxytocin, a neuropeptide that the body produces, has shown some benefit in reducing the use of cannabis when administered intranasally in combination with motivational enhancement therapy sessions, though the treatment effect did not persist between sessions.CB1 antagonists such as rimonabant have been tested for utility in CUD.
- Repurposable Drugs
-
As of my latest available information, there are no specific drugs that are widely accepted and repurposed exclusively for the treatment of cannabis dependence. However, several medications are being studied for their potential benefits in managing cannabis dependence:
1. **N-Acetylcysteine (NAC)**: An amino acid supplement that has shown promise in reducing cannabis use and craving by modulating glutamate pathways.
2. **Gabapentin**: Traditionally used for seizures and neuropathic pain, gabapentin has shown some potential in reducing cannabis withdrawal symptoms.
3. **Bupropion**: An antidepressant and smoking cessation aid that has been studied for its potential to reduce cannabis use, though results are mixed.
4. **Topiramate**: An anticonvulsant that has been investigated for its ability to reduce cannabis cravings and withdrawal symptoms.
These medications are still under research, and their effectiveness and safety profiles are not yet fully established for cannabis dependence treatment. Always consult healthcare professionals for personalized medical advice. - Metabolites
-
Cannabis dependence is characterized by the compulsive use of cannabis despite significant negative consequences. The primary psychoactive component of cannabis is Δ9-tetrahydrocannabinol (THC).
Metabolites:
- The primary active metabolite of THC is 11-hydroxy-THC (11-OH-THC).
- Another significant metabolite is 11-nor-9-carboxy-THC (THC-COOH), which is often measured in drug tests as it remains in the body for a longer period.
Detection:
- In urine, THC-COOH can be detected for several days to weeks after use, depending on the frequency and amount of cannabis consumed.
- Blood tests usually detect THC and its metabolites for a shorter duration, typically up to a few days.
- Hair tests can detect cannabis use for up to several months, as metabolites can be incorporated into the hair shaft.
Addiction/Dependence Symptoms:
- Cravings for cannabis
- Increased tolerance requiring more cannabis to achieve the same effect
- Withdrawal symptoms such as irritability, sleep difficulties, and decreased appetite when not using cannabis.
Treatment for cannabis dependence may include behavioral therapies, counseling, and support groups. - Nutraceuticals
- There are no widely recognized or well-established nutraceuticals specifically for treating cannabis dependence. Research is ongoing, and current interventions primarily focus on behavioral therapies and other forms of counseling. Nutraceuticals supplementing a balanced diet may support overall brain health and reduce substance craving, but their effectiveness specifically for cannabis dependence hasn't been conclusively proven. Always consult with a healthcare provider for personalized advice.
- Peptides
- In the context of cannabis dependence, peptides generally do not play a direct role. Cannabis dependence primarily affects the endocannabinoid system in the brain, particularly through interaction with cannabinoid receptors (CB1 and CB2). Peptides, which are short chains of amino acids, are more commonly associated with other physiological processes like immune response, digestion, and neuroregulation. Therefore, there isn't a significant or direct connection between peptides and cannabis dependence.